| Literature DB >> 30662958 |
J Jaime Miranda1,2, María Lazo-Porras1, Antonio Bernabe-Ortiz1, M Amalia Pesantes1, Francisco Diez-Canseco1, Socorro Del Pilar Cornejo3, Antonio J Trujillo4.
Abstract
Background: Incentives play a role in introducing health-related benefits, but no interventions using mixed incentives, i.e. a combination of individual and group incentives, have been tested in individuals with type 2 diabetes mellitus (T2DM). We evaluated the feasibility of implementing individual- and mixed-incentives, with and without a supportive partner, on glycated haemoglobin (HbA1c) control and weight loss among patients with T2DM.Entities:
Keywords: Diabetes; Diabetes control; Diabetes management; Peru; behavioral economics; complex interventions; feasibility trial
Year: 2019 PMID: 30662958 PMCID: PMC6325609 DOI: 10.12688/wellcomeopenres.14824.3
Source DB: PubMed Journal: Wellcome Open Res ISSN: 2398-502X
Figure 1. Flowchart of study participants.
Baseline demographic and clinical characteristics.
| Arm 1
| Arm 2
| Arm 3
| |
|---|---|---|---|
| Sociodemographic profile | |||
| Female | 12/18 (67%) | 12/18 (67%) | 12/18 (67%) |
| Age (years), mean ± SD | 54.7 ± 9.8 | 55.5 ± 9.8 | 54.2 ± 7.6 |
| Education | |||
| Primary level or lower | 4/18 (22%) | 3/18 (17%) | 2/18 (11%) |
| Primary to secondary level | 5/18 (28%) | 10/18 (56%) | 8/18 (44%) |
| Secondary level or higher | 9/18 (50%) | 5/18 (28%) | 8/18 (44%) |
| Occupation | |||
| Employed | 8/18 (44%) | 9/18 (50%) | 9/18 (50%) |
| Unemployed | 5/18 (28%) | 2/18 (11%) | 2/18 (11%) |
| Housewife | 5/18 (28%) | 7/18 (39%) | 7/18 (39%) |
| Monthly income
[ | |||
| <850 PEN (<$264 USD) | 3/16 (19%) | 5/16 (31%) | 6/15 (40%) |
| 850-1,500 PEN ($264-$465 USD) | 10/16 (62%) | 7/16 (44%) | 4/15 (27%) |
| >1,500 PEN (>$465 USD) | 3/16 (19%) | 4/16 (25%) | 5/15 (33%) |
| Highest contribution to household’s income (yes) | 8/18 (44%) | 5/18 (28%) | 6/18 (33%) |
| Living with a partner (yes) | 11/18 (61%) | 10/18 (56%) | 15/18 (83%) |
| Household size (number of people), mean ± SD | 5.4 ± 4.2 | 4.2 ± 2.1 | 4.8 ± 2.1 |
| Diabetes-related profile | |||
| Time of diabetes diagnosis (years), mean ± SD | 6.6 ± 5.8 | 7.4 ± 8.4 | 5.9 ± 3.8 |
| Self-reported health (very good, good, fair)
| 14/15 (93%) | 16/17 (94%) | 13/18 (72%) |
| Had HbA1c measured in the last 3 months (yes) | 11/17 (65%) | 11/16 (69%) | 12/18 (67%) |
| Pharmacological treatment | |||
| Oral hypoglycemic drugs | 12/17 (71%) | 11/17 (64%) | 17/18 (94%) |
| Insulin | 1/17 (6%) | 3/17 (18%) | 0/18 (0%) |
| Both | 4/17 (23%) | 3/17 (18%) | 1/18 (6%) |
| Has diabetes complications | |||
| Eye problems | 11/18 (61%) | 13/18 (72%) | 13/18 (72%) |
| Foot ulcers | 2/18 (11%) | 2/18 (11%) | 0/18 (0%) |
| Renal problems or dialysis | 5/18 (28%) | 3/18 (17%) | 3/18 (17%) |
| Health-related profile | |||
| Comorbidities | |||
| Hypertension | 5/18 (28%) | 5/18 (28%) | 4/18 (22%) |
| Stroke | 1/18 (6%) | 2/18 (11%) | 1/18 (6%) |
| Depression (PHQ-9 >14) | 0/18 (0%) | 1/18 (6%) | 2/18 (11%) |
| Lifestyle and behavioral risk factors | |||
| Alcohol consumption (never, last 12 months) | 8/18 (44%) | 7/18 (39%) | 7/18 (39%) |
| Cigarette smoking (yes, at least one per day) | 2/18 (11%) | 1/18 (6%) | 3/18 (17%) |
| Walking 30 min (≤1 day per week) | 7/18 (39%) | 6/18 (33%) | 5/18 (28%) |
| Fruit intake (<1 portion per day) | 8/18 (44%) | 3/18 (17%) | 2/18 (11%) |
| Vegetable intake (<1 portion per day) | 4/18 (22%) | 3/18 (17%) | 3/18 (17%) |
All values presented correspond to n (%), unless otherwise stated.
†Peru minimum salary wage for year 2017 was 850 PEN, the category used for monthly income. Average exchange rate for year 2017 was 1 PEN = 0.31 USD. *Self-reported health, the corresponding figures (not shown) belong to poor or very poor categories.
Primary and secondary outcomes at baseline and 3-month results, by study arms.
| Arm 1 Individual | Arm 2 Mixed
| Arm 3 Mixed
| Arm 2 vs.
| Arm 3 vs.
| |
|---|---|---|---|---|---|
| Primary outcome | |||||
| HbA1c (%) | |||||
| Baseline | 8.5 ± 2.2 | 7.9 ± 3.1 | 8.2 ± 2.1 | 0.99 | 0.99 |
| 3 months | 6.9 ± 1.7 | 7.2 ± 1.6 | 7.1 ± 1.7 | 0.99 | 0.99 |
| Δ (3-mo vs
|
|
|
| 0.05 | 0.05 |
| Secondary
| |||||
| Weight (Kg) | |||||
| Baseline | 76.9 ± 10.7 | 84.5 ± 17.4 | 85.1 ± 22.3 | 0.59 | 0.48 |
| 3 months | 72.6 ± 11.0 | 82.2 ± 17.2 | 84.7 ± 22.7 | 0.45 | 0.20 |
| Δ (3-mo vs
|
| -0.4 ± 2.5 | -0.4 ± 3.0 | 0.04 | 0.03 |
| BMI (Kg/m 2) | |||||
| Baseline | 33.1 ± 4.8 | 34.6 ± 6.0 | 36.1 ± 10.1 | 0.99 | 0.67 |
| 3 months | 31.6 ± 5.2 | 33.8 ± 5.7 | 36.0 ± 9.8 | 0.99 | 0.31 |
| Δ (3-mo vs
|
| -0.2 ± 1.0 | -0.2 ± 1.4 | 0.05 | 0.05 |
Values in bold are those significant (p<0.05) when comparing difference between 3-month and baseline assessment (within each arm).
Primary and secondary outcomes at baseline and 3-month results, by study’s subgroups.
| Subgroups by number of
| Subgroups by number of payments provided in
| ||||||
|---|---|---|---|---|---|---|---|
| Lower | Higher | p-value
| 0 | 1 | 2 | p-value
| |
| N = 24 | N = 30 | N = 24 | N = 21 | N = 9 | |||
| Primary outcome | |||||||
| HbA1c (%) | |||||||
| Baseline | 8.0 ± 3.0 | 8.3 ± 2.0 | 0.66 | 7.9 ± 3.1 | 9.0 ± 1.9 | 7.1 ± 1.1 | 0.11 |
| 3 months | 6.8 ± 1.3 | 7.1 ± 1.7 | 0.64 | 7.5 ± 2.1 | 7.3 ± 1.3 | 6.0 ± 0.4 | 0.09 |
| Δ (3-mo vs
| -0.8 ± 1.5 |
| 0.49 | -0.6 ± 1.6 |
|
| 0.07 |
| Secondary
| |||||||
| Weight (Kg) | |||||||
| Baseline | 85.2 ± 16.9 | 79.7 ± 17.9 | 0.26 | 78.3 ± 16.8 | 83.4 ± 11.8 | 89.6 ± 27.6 | 0.23 |
| 3 months | 84.2 ± 19.2 | 77.7 ± 17.4 | 0.28 | 74.8 ± 15.7 | 82.7 ± 13.9 | 85.1 ± 26.9 | 0.27 |
| Δ (3-mo vs
| 0.3 ± 1.9 |
| 0.009 | 0.6 ± 1.9 |
|
| <0.001 |
| BMI (Kg/m 2) | |||||||
| Baseline | 35.5 ± 6.4 | 33.9 ± 8.0 | 0.42 | 33.5 ± 6.0 | 33.8 ± 4.2 | 39.3 ± 13.2 | 0.10 |
| 3 months | 35.5 ± 6.7 | 33.0 ± 7.5 | 0.29 | 32.4 ± 5.1 | 33.4 ± 5.1 | 37.3 ± 12.6 | 0.25 |
| Δ (3-mo vs
| 0.1 ± 0.8 |
| 0.01 | 0.2 ± 0.8 |
|
| <0.001 |
Values in bold are those significant (p<0.05) when comparing difference between 3-month and baseline assessment (within each arm). * p-values in the columns are for comparisons between subgroups.